Aspira Women's Health Inc. announced that it has entered into a securities purchase agreement with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1,264,739 shares of its common stock and warrants to purchase an equal number of shares of Common Stock at a combined offering price of $1.53 per share and warrant through a private placement financing for the aggregate gross proceeds of $1,935,051 on June 30, 2024. The warrants will be exercisable for three years after date of issuance and have an exercise price of $2.25 per share. The Offering is expected to close by July 8, 2024 subject to customary closing conditions.

The securities being issued and sold in this private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements.